This Article Full Text Full Text (PDF) Supplemental Data Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Feng, S.-M. Articles by Earp, H. S. Search for Related Content PubMed PubMed Citation Articles by Feng, S.-M. Articles by Earp, H. S., III

The HER4 Cytoplasmic Domain, But Not Its C Terminus, Inhibits Mammary Cell Proliferation

University of North Carolina Lineberger Comprehensive Cancer Center (S.-M.F., C.I.S., D.H., H.Z., X.Y., L.S.C., R.D., R.S.M.-C., H.S.E.), Department of Radiation Oncology (C.I.S.), Department of Genetics (R.S.M.-C.), and Department of Medicine and Pharmacology (H.S.E.), University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, North Carolina 27599

Address all correspondence and requests for reprints to: H. Shelton Earp, III, Lineberger Comprehensive Cancer Center, University of North Carolina Chapel Hill, 102 Mason Farm Road, Chapel Hill, North Carolina 27599. E-mail: hse{at}med.unc.edu.

Unlike the proliferative action of other epidermal growth factor (EGF) receptor family members, HER4/ErbB4 is often associated with growth-inhibitory and differentiation signaling. These actions may involve HER4 two-step proteolytic processing by intramembraneous -secretase, releasing the soluble, intracellular 80-kDa HER4 cytoplasmic domain, s80^HER4. We demonstrate that pharmacological inhibition of either -secretase activity or HER4 tyrosine kinase activity blocked heregulin-dependent growth inhibition of SUM44 breast cancer cells. We next generated breast cell lines stably expressing GFP-s80^HER4 [green fluorescent protein (GFP) fused to the N terminus of the HER4 cytoplasmic domain, residues 676-1308], GFP-CT^HER4 (GFP fused to N terminus of the HER4 C-terminus distal to the tyrosine kinase domain, residues 989-1308), or GFP alone. Both GFP-s80^HER4 and GFP-CT^HER4 were found in the nucleus, but GFP-s80^HER4 accumulated to a greater extent and sustained its nuclear localization. s80^HER4 was constitutively tyrosine phosphorylated, and treatment of cells with a specific HER family tyrosine kinase inhibitor 1) blocked tyrosine phosphorylation; 2) markedly diminished GFP-s80^HER4 nuclear localization; and 3) reduced signal transducer and activator of transcription (STAT)5A tyrosine phosphorylation and nuclear localization as well as GFP-s80^HER4:STAT5A interaction. Multiple normal mammary and breast cancer cell lines, stably expressing GFP-s80^HER4 (SUM44, MDA-MB-453, MCF10A, SUM102, and HC11) were growth inhibited compared with the same cell line expressing GFP-CT^HER4 or GFP alone. The s80^HER4-induced cell number reduction was due to slower growth because rates of apoptosis were equivalent in GFP-, GFP-CT^HER4-, and GFP-s80^HER4-expressing cells. Lastly, GFP-s80^HER4 enhanced differentiation signaling as indicated by increased basal and prolactin-dependent ß-casein expression. These results indicate that surface HER4 tyrosine phosphorylation and ligand-dependent release of s80^HER4 are necessary, and s80^HER4 signaling is sufficient for HER4-dependent growth inhibition.

This article has been cited by other articles:

				R. S. Muraoka-Cook, M. Sandahl, D. Hunter, L. Miraglia, and H. S. Earp III Prolactin and ErbB4/HER4 Signaling Interact via Janus Kinase 2 to Induce Mammary Epithelial Cell Gene Expression Differentiation Mol. Endocrinol., October 1, 2008; 22(10): 2307 - 2321. [Abstract] [Full Text] [PDF]